COMP <GO>
NAGE vs MRK // PIOTROSKI F-SCORE QUALITY
Niagen Bioscience Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: NAGE 4
— MRK 8
■ METRIC PARITY
LAST: $2.50 (-1.57%) • MKT CAP: $197.8M
piotroski-score
7/9
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NAGE VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NAGE | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.30% | 74.80% | -10.50 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.80% | 20.70% | -3.90 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.2x | 15.3x | -3.10 | NAGE | /valuation <GO> |
| Free Cash Flow Yield | 6.83% | 3.42% | +3.41 | NAGE | /fcf-yield <GO> |
| Operating Margin | 12.60% | 34.30% | -21.70 | MRK | /operating-margins <GO> |
| Net Profit Margin | 13.40% | 28.10% | -14.70 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 29.90% | 1.30% | +28.60 | NAGE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.40 | 5.19 | -0.79 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.1 | 51.7 | -8.60 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 9.6x | 18.4x | -8.80 | NAGE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $197.8M | $361.02B | -$360.82B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NAGE REV | MRK REV | NAGE GROSS % | MRK GROSS % | NAGE FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $129.4M | $65.01B | 64.3% | 74.8% | $13.5M | $12.36B |
| FY 2024 | $99.6M | $64.17B | 61.8% | 76.3% | $12.1M | $18.10B |
| FY 2023 | $83.6M | $60.12B | — | — | $7.1M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NAGE // BETA —
MRK // BETA 0.92